Maintenance Notice (4:00 AM November 1 - 9:30 AM November 1, 2025): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
Published TCIMAIL newest issue No.199
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 179688-29-0 | Product Number: B4270
6,7-Bis(2-methoxyethoxy)-3H-quinazolin-4-one
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- 6,7-Bis(2-methoxyethoxy)-4(3H)-quinazolinone
- 6,7-Bis(2-methoxyethoxy)-3,4-dihydroquinazolin-4-one
- 6,7-Bis(2-methoxyethoxy)-4-hydroxyquinazoline
- 6,7-Bis(2-methoxyethoxy)-4-quinazolinol
Product Documents:
| Size | Unit Price | Belgium | Japan* | Quantity |
Shipping Information
|
|---|---|---|---|---|---|
| 1G |
€46.00
|
Contact Us | 2 |
|
|
| 5G |
€160.00
|
Contact Us | 3 |
|
* Stock available in Belgium: Shipment on the same day
* Stock available in Japan: Please check the Shipping Simulation for estimated shipments. (excludes regulated items and dry ice shipments)
| Product Number | B4270 |
Purity / Analysis Method 
|
>98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__1__4H__1__8N__2O__5 = 294.31 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature
|
Room Temperature (Recommended in a cool and dark place, <15°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Air Sensitive |
| CAS RN | 179688-29-0 |
| Reaxys Registry Number | 10087641 |
| PubChem Substance ID | 253660263 |
| MDL Number | MFCD02678087 |
Specifications
| Appearance | White to Light yellow to Light orange powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| Melting point | 190.0 to 194.0 °C |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 192 °C |
GHS
Related Laws:
Transport Information:
| HS Number | 2933599590 |
Application
A Key Synthetic Intermediate of Erlotinib
This product is a key synthetic intermediate of erlotinib which is a receptor tyrosine kinase inhibitor acting on the epidermal growth factor receptor (EGFR), such as gefitinib [G0546].
References
- Improved synthesis of substituted 6,7-dihydroxy-4-quinazolineamines: tandutinib, erlotinib and gefitinib
- Improved Synthesis of Gefitinib and Erlotinib Hydrochloride-Anticancer Agents
- Modified Synthesis of Erlotinib Hydrochloride
- Separation and determination of process-related impurities of erlotinib using reverse-phase HPLC with a photo-diode array detector
PubMed Literature
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.